THE USAGE OF METOPROLOL TARTRATE IN ELDERLY AND OLD PATIENTS WITH CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE

• Main Authors: E. B. Nagaytseva, I. V. Vologdina, M. D. Malykina, I. V. Goncharova
• Format: Article
• Language: Russian
• Published: «FIRMA «SILICEA» LLC 2003-06-01
• Series: Российский кардиологический журнал
• Subjects: ischemic heart disease; chronic heart failure; elderly and old patients; эгилок®; egiloc®
• Online Access: https://russjcardiol.elpub.ru/jour/article/view/1751
• ISSN: 1560-4071; 2618-7620

Aim of the study. To evaluate clinical efficacy and safety of metoprolol (Egiloc®) in treatment of Coronary Heart Disease (CHDO complicated by chronic heart failure (CHF) in elderly and old patients with normal and elevated blood pressure (BP), selection of optimal dose.Materials and methods. 43 patients (mean age with 78.6 ± 3.8 years) with CHD complicated by CHF NYHA II functional class were treated by Egiloc® 25-100 mg daily for 17 days. Egiloc was added to baseline treatment with mononitrates and angiotensin converting enzyme (ACE) inhibitors. Clinical data, daily BP monitoring, echocardiography and 6-minutes walking test were evaluated.Results. Treatment with Egiloc® was accompanied by a reliable decrease in angina frequency and clinical features of CHF with no reliable changes in ejection fraction. There were no cases of hypotension in patients with normal BP levels taking 25-50 mg Egiloc® daily. Patients taking 25-50 mg Egiloc® daily demonstrated a reliable increase of physical stress tolerability, a reliable BP decrease and decreased incidence of BP elevations on BP daily monitoring. There were no cases of Egiloc® discontinuation die to poor tolerability.Conclusion. The results indicate that treatment with Egiloc® 25-100 mg daily is safe and effective in elderly and old coronary patients with CHF NYHA II functional class with normal and elevated BP. The drug's effect is dose-dependent.